Reducing barriers to better treatments by designing and delivering high-quality, large-scale, and global clinical trials at a fraction of the current industry cost.

£15,000,000 / January 2026, October 2022

Expanding professionalized education and mentoring programs to support the next generation of respiratory virus specialists.

£843,900 / December 2025

Evaluating the feasibility of glycol vapors as a scalable emergency intervention for inactivating airborne pathogens in indoor settings.

$2,000,000 / November 2025

Establishing the operational framework for a research-integrated childcare facility to evaluate innovative infection management strategies and technologies.

$1,000,000 / September 2025

Creating the first universal testing platform to provide fast, accurate, digital imaging-based identification for infectious disease pathogens.

£840,00 Bridge / June 2025, £700,00 PreSeed / October 2023

Filling critical gaps in immunity-driven influenza dynamics through innovative molecular methods and multi-source longitudinal data.

$7,233,895 / May 2025

In partnership with the University of Queensland, identifying influenza transmission risk through gene expression profiles associated with high viral load and shedding prior to infection.

$1,314,947 AUD / March 2025

Advancing a pathway to influenza-resistant poultry to minimize disease transmission between animals and humans.

$2,443,750 / February 2025

Developing INNA-051, a simple-to-administer, virus-agnostic, seasonally delivered product designed to minimize the impact of viral respiratory infections.

$5,000,000 Series B / February 2025

Capturing acute viral infection dynamics over time to identify immune correlates of reduced shedding and transmission potential.

$1,285,670 / January 2025

Leveraging multidisciplinary approaches to investigate the transmission of respiratory pathogens and strategies to limit their spread.

$14,000,000 / December 2024

Optimizing a non-thermal, plasma-powered prototype device for maskless personal protection from airborne pathogens.

$200,000 / December 2024

Accelerating the development, translation, and implementation of new technologies for disease diagnosis while ensuring health equity and justice.

$1,000,000 / December 2024

Facilitating collaborative approaches among influenza research funders to maximize impactful and efficient investments.

$100,000 / November 2024

Conducting clinical studies of a drug-free nasal spray designed to block and neutralize airborne influenza virus and other respiratory pathogens.

$384,000 / November 2024

Leading INVITED, a multicenter, prospective randomized clinical trial among Type 1 diabetes patients to improve our understanding of the protective effect of influenza vaccination.

2,768,181 DKK / September 2024, October 2022

Developing a safe, effective, and broadly protective influenza vaccine to prevent infection with, or transmission of, influenza.

£2,344,885 / June 2024

Leading virus species identification and analysis for the New York City Virus Hunters community science program.

$1,073,042 / May 2024

Incorporating genotype accessibility into influenza virus evolutionary predictions.

$1,370,388 / May 2024

Equipped schools and education stakeholders with information and guidance to improve ventilation and air filtration in classrooms.

$955,710 / May 2024, October 2021, August 2021

Advanced the development of Respiratory Scout, a low-cost molecular test to diagnose influenza and other respiratory virus infections.

$161,000 / March 2024

• Conducting far-UVC light ocular and stratum corneum safety studies in diverse human populations.

• $1,662,490 / March 2024

Evaluated the immunogenicity and protection of an intranasal universal influenza vaccine candidate against wild-type transmission in ferrets.

$406,000 / December 2023

Advanced a handheld, rapid result, breath-based diagnostic for the detection of multiple respiratory pathogens.

$3,595,280 / November 2023

Explored inhalable, broad-spectrum antivirals to provide extended prophylaxis against infectious diseases.

$159,000/ October 2023

• Adapted graphene-based biosensors for the selective detection of influenza.

• $1,348,454 / June 2023

Establishing a reproducible, experimental human infection model of influenza virus transmission and evaluating interventions.

$3,479,305 / March 2023

Evaluating treatments for severe and complicated influenza infections in hospitalized patients with RECOVERY FLU, a cost-efficient, adaptive platform clinical trial.

£11,416,263 / December 2022

Led a multidisciplinary, multi-institutional effort to observe and examine the reintroduction and transmission of influenza in New Zealand and identify novel immunological markers of severe influenza disease.

11,340,572 NZD / December 2022, May 2021

Developing fast, accurate, and affordable molecular tests for routine use by everyone, including consumers in the home, employees in the workplace, and students at school.

Series C / November 2022, Series B / April 2021

Created an immersive approach to science education to unlock the potential of the next generation of influenza researchers in New York City.

$1,146,303 / July 2022, April 2020

Identified effective, scalable interventions for promoting immunizations.

$2,435,763 / March 2022, June 2021, October 2020

Leading the Multidisciplinary InvesTIGAtion of Transmission to Ease inFLUenza (MITIGATE FLU) study to transform our understanding of influenza virus transmission.

$8,792,291 / February 2022

Optimized ventilation system operations to minimize airborne infectious disease transmission, pollutant exposure, and energy consumption.

$327,539 / November 2021

Promoted open science in biomedical fields and expanded the publication of null and negative influenza research findings and replication studies.

$18,398,983 / August 2021, April 2020, August 2019

Developed and deployed ultra-sensitive genomic and CRISPR technologies to detect pathogens in multiple, connected settings to prevent pandemics before they start.

$5,000,000 / February 2021

Combined diagnostic technology and information-sharing platforms to connect early warning data to the public health community.

$11,250,000 / December 2020